PARP1 and ovarian carcinoma: Despite the demonstrated efficacy of PARP inhibition in BRCA-mutated breast and ovarian cancers, most patients eventually develop resistance, as evidenced by a median progression-free survival of less than 1 year in the major PARPi clinical trials.